前立腺癌の抗男性ホルモン療法と再燃

概要

論文の詳細を見る
One hundred and fifty-two patients first treated at Department of Urology, Chiba University school of Medicine from June 1960 to December 1977 were followed, and the following results were obtained. 1) The actuarial 5-year and 1O-year survival rates of all cases were 40% and 12%, respectively. When classified according to the degree of advancement, 5-year survival rates of stage A,B,C and D were 67%, 70%, 43% and 28%, respectively. Ten-year survival rates of each stage, on the other hand, were 67%, 46%, 11% and 0%, respectively. 2) Eighty-two patients had received anti-androgenic therapy as an initial therapy. The actuarial 5-year survival rates were 56% in stage C and 34% in stage D, thus indicating a slightly better prognosis than the entire group. 3) Those who were treated with anti-androgenic drugs were divided into the sufficient-dose and insufficient-dose groups, and the actuarial survival rates were examined. Five-year survival rates of the former group were 64% in stage C and 47% in stage D. Those of the latter group were 31% and 22%, respectively. The prognosis proved better in the sufficient-dose group.
社団法人日本泌尿器科学会の論文
1979-11-20